Physician profile
Robert Patrick Mcmorrow
NPI 1093027013
$2,986.48
in general payments reported to CMS, 2019-2025
11 companies · $2,346 in 2025
The $2,346 reported for 2025 was more than what 93% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $52.58 · 2021: $146 · 2022: $102 · 2023: $34.55 · 2024: $110 · 2025: $2,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,063 · Food and Beverage: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,062.50 |
| Food and Beverage | $427.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $2,478.68 | 2019-2025 | Sublocade |
| Abbvie INC. | $147.01 | 2020-2025 | |
| Orexo US, INC. | $99.49 | 2021-2025 | Zubsolv |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.22 | 2025 | Caplyta |
| Gilead Sciences, INC. | $44.20 | 2022-2024 | |
| Lilly USA, LLC | $39.75 | 2024-2025 | Zepbound, Mounjaro |
| Alkermes, INC. | $38.37 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $31.81 | 2025 | Airsupra |
| Novo Nordisk INC | $24.21 | 2025 | Wegovy |
| Braeburn INC. | $19.19 | 2025 | Brixadi |
| Takeda Pharmaceuticals U.S.A., INC. | $18.55 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcmorrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.